The LEDGIN GS-9822 inhibits HIV-2 infection and enhances HIV-2 latency.

However, reactivation, as measured by the fold increase in eGFP-positive cells, seemed to show a decreasing trend in cells pre-treated with increasing concentrations of GS-9822 for HIV-2 OGH as measured at 48 h ( Fig. 4b and e : data from one experiment and summary data from four experiments, respectively) and to a lesser degree at 24 h ( Fig.

also in 47,180 other papers